Proven Efficacy of ‘Zolere’ for Multiple Food Allergies: Expanding Indications
Zolair Demonstrates Effectiveness Against Multiple Food Allergies
Table of Contents
- Zolair Demonstrates Effectiveness Against Multiple Food Allergies
- Zolair (Omalizumab) and Food Allergies: Your Questions Answered
- what is Zolair (omalizumab) and what is it used for?
- How effective is Zolair in treating multiple food allergies?
- How does Zolair work to treat food allergies?
- What is OIT (oral Immunotherapy) and how does it compare to Zolair?
- Who is eligible for zolair treatment for food allergies?
- what are the potential side effects of Zolair?
- Can allergenic foods be reintroduced after Zolair treatment?
- What is the significance of the OUtMATCH study?
- What is the status of biosimilars for Zolair?
- How are Novartis and Roche responding to the biosimilar competition?
- What are the sales figures for Zolair, and why are they critically important?
- Key Differences Between Zolair and OIT
Seoul (News1) – Research indicates that Zolair (omalizumab), an allergic asthma treatment co-developed by global pharmaceutical companies Novartis and Roche, is more effective than oral immunotherapy (OIT) in treating multiple food allergies. With the patent expiration of Zolair approaching this year, strategies to expand its indications are accelerating.
Positive Data from outmatch Study
According to industry sources on March 7, 2025, Novartis and roche recently announced positive data from phases 2 and 3 of the OUtMATCH phase 3 clinical trial, sponsored by the U.S. National Institutes of Health (NIH). The study showed that Zolair is more effective than existing treatments for multiple food allergies.
In February 2024, Zolair received approval from the U.S. Food and Drug Administration (FDA) as a treatment to reduce multiple food allergy reactions, including anaphylaxis, in adults and children (ages 1 and older).It is indeed the first case to receive FDA approval as a treatment for multiple food allergies.
Zolair’s Potential in Treating Multiple Food Allergies Confirmed
The phase 2 results of OUtMATCH indicate that Zolair is more effective than OIT, the existing treatment method, in treating multiple food allergies, and has a lower incidence of side effects. This study is the first clinical trial to directly compare Zolair and OIT, and is considered vital data that proves the difference between the treatments.
OIT is a treatment method that increases immune tolerance by gradually consuming small amounts of allergenic foods (allergens). OIT has severe side effects and risks causing serious allergic reactions such as anaphylaxis. In this study, the OIT group had a high incidence of side effects, resulting in many cases of treatment discontinuation.
Evaluating the Reintroduction of Allergenic Foods
Phase 3 of the study evaluated whether allergenic foods could be reintroduced into the diet after the end of Zolair treatment. The results showed that 82% of the 180 foods could be included in the diet after Zolair treatment. However, cases of side effects such as anaphylaxis were reported in a small number of patients, and additional research is underway.
Accelerating Strategies to Expand Indications Before Zolair Patent Expiration
Zolair is a “blockbuster drug” that recorded sales of $1.643 billion (approximately ₩2.4 trillion) last year. In 2023, it achieved sales of ₩5 trillion. This is why biosimilar developers are accelerating their efforts ahead of the expiration of Zolair’s patent this year.
The South Korean biosimilar company Celltrion (068270) has already received marketing authorization for Zolair’s biosimilar, ‘Omlyclo,’ in Europe and South Korea in May and June of last year. It is currently awaiting U.S. FDA marketing authorization.
Novartis and Roche are strengthening their competitiveness in the biosimilar market by expanding the indications of Zolair. Based on the results of Zolair’s phase 3 clinical trial, additional research is underway, and it is indeed expected to present a new paradigm for food allergy treatments in the future.
Zolair (Omalizumab) and Food Allergies: Your Questions Answered
Zolair (omalizumab) is emerging as a promising treatment for individuals with multiple food allergies. This Q&A article provides comprehensive information about Zolair, its effectiveness, and its role in managing food allergies.
what is Zolair (omalizumab) and what is it used for?
Zolair (omalizumab) is a medication initially developed as an allergic asthma treatment. it is co-developed by Novartis and Roche. The drug has been found effective in reducing the risk of severe allergic reactions,including anaphylaxis,in people with food allergies.
Specifically, Zolair is now also used to treat:
Allergic asthma. (Search Result 1)
Nasal polyps. (Search Result 1)
Chronic hives. (Search Result 1)
How effective is Zolair in treating multiple food allergies?
Research indicates that Zolair is more effective than oral immunotherapy (OIT) in treating multiple food allergies. Positive data from phases 2 and 3 of the OUtMATCH clinical trial confirmed these findings.
Key Takeaways from the OUtMATCH Study:
Efficacy: Zolair demonstrated superior efficacy compared to OIT for multiple food allergies.
Side Effects: Zolair had a lower incidence of side effects compared to OIT.
Food Reintroduction: 82% of 180 allergenic foods coudl be reintroduced into the diet after Zolair treatment.
How does Zolair work to treat food allergies?
Zolair works by reducing the risk of allergic reactions, including anaphylaxis, in individuals with multiple food allergies. It helps to prevent symptoms when regularly administered, but is not for emergency allergic reactions (Search Result 2).
What is OIT (oral Immunotherapy) and how does it compare to Zolair?
OIT (Oral Immunotherapy) is a treatment method that increases immune tolerance by gradually consuming small amounts of allergenic foods. While OIT can be effective, it often comes with severe side effects, including the risk of anaphylaxis, leading to frequent treatment discontinuations. The OUtMATCH study demonstrated that Zolair is more effective and has fewer side effects than OIT.
Who is eligible for zolair treatment for food allergies?
In February 2024, the U.S. Food and Drug Administration (FDA) approved Zolair for reducing allergic reactions, including anaphylaxis, in adults and children ages 1 and older with multiple food allergies.
what are the potential side effects of Zolair?
While the provided article does not list specific side effects, it does mention that Zolair has a lower incidence of side effects compared to OIT.
Important Note: Always consult with a healthcare professional for a complete list of side effects and to determine if Zolair is right for you.* (Search Result 1)
Can allergenic foods be reintroduced after Zolair treatment?
The phase 3 results of the OUtMATCH study showed that 82% of 180 allergenic foods could be included back into the diet after Zolair treatment. However, some patients experienced side effects like anaphylaxis, indicating a need for ongoing research in this area.
What is the significance of the OUtMATCH study?
The OUtMATCH study is the first clinical trial to directly compare Zolair and OIT for multiple food allergies.It provides crucial data demonstrating the differences between the two treatments, especially highlighting Zolair’s improved efficacy and reduced side effects.
What is the status of biosimilars for Zolair?
With the patent expiration of Zolair approaching, biosimilar developers are accelerating their efforts. Celltrion, a South Korean company, has already received marketing authorization for its Zolair biosimilar, ‘Omlyclo,’ in Europe and South Korea. They are currently awaiting U.S. FDA approval.
How are Novartis and Roche responding to the biosimilar competition?
Novartis and Roche are focusing on expanding the indications of Zolair to strengthen their competitiveness in the biosimilar market. They are conducting additional research based on the phase 3 clinical trial results,aiming to establish Zolair as a new standard in food allergy treatments.
What are the sales figures for Zolair, and why are they critically important?
Zolair is a blockbuster drug with considerable sales figures.Last year, it recorded sales of $1.643 billion (approximately ₩2.4 trillion), and in 2023, it achieved sales of ₩5 trillion.These figures underscore the drug’s importance and market presence, driving the development of biosimilars and further research into its applications.
Key Differences Between Zolair and OIT
| Feature | Zolair (Omalizumab) | OIT (Oral Immunotherapy) |
| —————– | ———————————————– | ———————————————————- |
| Mechanism | Reduces risk of allergic reactions | Increases immune tolerance by gradual allergen consumption |
| Efficacy | More effective for multiple food allergies | Less effective, higher risk of side effects |
| Side Effects | Lower incidence of side effects | Higher incidence of side effects, including anaphylaxis |
| Food Reintroduction | 82% success rate in OUtMATCH study | Variable, depends on individual tolerance |
| FDA Approval | Approved for multiple food allergies (Feb 2024) | Not specifically approved for multiple food allergies |